(Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis

A compound of the formula I:

• ##STR13## wherein:
• Het is ArR.sup.1 R.sup.2 ;
• Ar is a bicyclic aromatic ring containing 8 or 9 members, one of which is 0 or S, and 0-2 of which is N, and the N-oxides thereof;
• R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.10 are independently hydrogen, halogen, perhalo lower alkenyl, lower alkyl, lower alkenyl, lower alkynyl, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --C(OH)R.sup.11 R.sup.11, --CO.sub.2 R.sup.12, --SR.sup.14, --S(O)R.sup.14, --S(O).sub.2 R.sup.14, --S(O).sub.2 NR.sup.15 R.sup.15, --OR.sup.15, --NR.sup.15 R.sup.15, --NR.sup.12 CONR.sup.15 R.sup.15, --COR.sup.16, CONR.sup.15 R.sup.15, or --(CH.sub.2).sub.t R.sup.21 ;
• R.sup.5 is hydrogen, --CH.sub.3, CF.sub.3, --C(O)H, X.sup.1 --R.sup.6 or X.sup.2 --R.sup.7 ;
• R.sup.6 and R.sup.9 are independently alkyl, alkenyl, --(CH.sub.2).sub.u Ph(R.sup.10).sub.2 or --(CH.sub.2).sub.u Th(R.sup.10).sub.2 wherein Ph is phenyl and Th is 2- or 3-thienyl;
• R.sup.7 is --CF.sub.3 or R.sup.6 ;
• R.sup.8 is hydrogen or X.sup.3 -R.sup.9
• each R.sup.11 is independently hydrogen or lower alkyl, or two R.sup.11 's on same carbon atom are joined to form a cycloalkyl ring of 3 to 6 carbon atoms;
• R.sup.12 is hydrogen, lower alkyl or --CH.sub.2 R.sup.21 ;
• R.sup.13 is lower alkyl or --(CH.sub.2).sub.r R.sup.21 ;
• R.sup.14 is --CF.sub.3 or R.sup.13 ;
• R.sup.15 is hydrogen, --COR.sup.16, R.sup.13, of two R.sup.15 's on the same nitrogen may be joined to form a monocyclic heterocyclic ring of 4 to 6 atoms containing up to 2 heteroatoms chosen from O, S, or N;
• R.sup.16 is hydrogen, --CF.sub.3, lower alkyl, lower alkenyl, lower alkynyl or --(CH.sub.2).sub.r R.sup.21 ;
• R.sup.17 is --(CH.sub.2).sub.s --C(R.sup.18 R.sup.18)--(CH.sub.2).sub.s --R.sup.19 or --CH.sub.2 CONR.sup.15 R.sup.15.
• R.sup.18 is hydrogen or lower alkyl;
• R.sup.19 is a) a monocyclic or bicyclic heterocyclic ring containing from 3 to 9 nuclear carbon atoms and 1 or 2 nuclear hetero-atoms selected from N, S or 0 and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
• b) the radical W--R.sup.20 ;
• R.sup.20 is alkyl or --COR.sup.23 ;
• R.sup.21 is phenyl substituted with 1 or 2 R.sup.22 groups;
• R.sup.22 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfonyl, lower alkylcarbonyl, --CF.sub.3, --CN, --NO.sub.2 or --N.sub.3 ;
• R.sup.23 is alkyl, cycloalkyl, or monocyclic monoheterocyclic ring;
• R.sup.24 is the residual structure of a standard amino acid, or R.sup.18 and R.sup.24 attached to the same N can cyclize to form a proline residue;
• m is 0 or 1;
• n is 0 to 3;
• p is 1 to 3 when m is 1;
• p is 0 to 3 when m is 0;
• r is 0 to 2;
• s is 0 to 3;
• t is 0 to 2;
• u is 0 to 3;
• W is 0, S or NR.sup.15 ;
• X.sup.1 is 0 or NR.sup.15 ;
• X.sup.2 is CO, CR.sup.11 R.sup.11, S, S(O), or S(O).sub.2 ;
• X.sup.3 is CO, CR.sup.11 R.sup.11, S(O).sub.2, or a bond;
• X.sup.4 is CH.dbd.CH, CH.sub.2 --yl, or Y.sup.1 ---CH2;
• Y is X.sup.1 or X.sup.2 ;
• Y.sup.1 is O, S, S(O).sub.2, or CH.sub.2 ;
• Q is --CO.sub.2 R.sup.12, --CONHS(O).sub.2 R.sup.14, --NHS(O).sub.2 R.sup.14, --S(O).sub.2 NHR.sup.15, --CONR.sup.15 R.sup.15, --CO.sub.2 R.sup.17, --CONR.sup.18 R.sup.24, --CR.sup.11 R.sup.11 OH, or 1H- or 2H-tetrazol-5-yl;
• or a pharmaceutically acceptable salt thereof.